Retrophin Announces Top-Line Results From Pivotal Phase 3 Fort Study In Pkan On-Track For 3Q 2019; Announces Enrollment Ongoing In Phase 3 Clinical Trials Of Sparsentan For Patients With Rare Nephropathies Fsgs And Igan